Using Lyumjev in conventional CSII pump therapy provides more effective BRRs prior to exercise compared with Humalog, with fewer hypoglycemic events in active adults with type 1 diabetes.
Ultrarapid Lispro (Lyumjev) Has an Improved Pharmacokinetic Profile for Exercise Compared With Humalog, Resulting in Less Exercise-Associated Hypoglycemia in Adults With Type 1 Diabetes on Open-Loop Continuous Subcutaneous Insulin Infusion
Jennifer Leohr·Michael C. Riddell·Lauren V. Turner·ARITRA GHOSH·David E. Coutant·Elizabeth LaBell·Alexander Abitbol